Browse studies

Find your next paid study

6 recruiting studies matching your filters

Phase 1 First-in-Human, Dose Escalation and Dose Expansion Study of RYZ401, a Novel Radiopharmaceutical Therapy Labeled With Actinium-225, in Subjects With Neuroendocrine Tumors and Other Solid Tumors Expressing Somatostatin Receptors.

The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate p…

GEP-NETGastroenteropancreatic Neuroendocrine TumorGastroenteropancreatic Neuroendocrine Tumor Disease+6 more

Estimated

~$10 – $8,750

RayzeBio, Inc.NCT07165132

Phase 3

A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients Newly Diagnosed With Grade 1 and Grade 2 (Ki-67 <10%) Advanced GEP-NET With High Disease Burden (NETTER-3)

The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LA…

Somatostatin Receptor Positive (SSTR+)Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)

Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT06784752

Treatment Patterns and Outcomes in GEP NET: A Retrospective Observational Cohort Study (PRIME Initiative)

This study aims to characterize current treatment patterns and clinical outcomes among newly diagnosed GEP-NET patients in the United States using open-source …

Gastroenteropancreatic Neuroendocrine Tumor

Estimated

~$10 – $1,050

Novartis PharmaceuticalsNCT07635316

Phase 1

A Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Tumors

This study is Phase I/IIa First-in-Human Study of \[212Pb\]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Tumors

Neuroendocrine Tumors UnresectableNeuroendocrine Tumor MetastaticGastroenteropancreatic Neuroendocrine Tumor+4 more

Estimated

~$10 – $8,750

Perspective TherapeuticsNCT05636618

Phase 3

Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy

This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ…

GEP-NETGastroenteropancreatic Neuroendocrine TumorGastroenteropancreatic Neuroendocrine Tumor Disease+4 more

Estimated

~$10 – $8,750

RayzeBio, Inc.NCT05477576

Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine

The specific aim is of this study is to gain a better understanding of the patient characteristics, treatment responses, survival outcomes, and adverse events …

Neuroendocrine TumorsGastroenteropancreatic Neuroendocrine Tumor

Estimated

~$10 – $750

Methodist Health SystemNCT04090034